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Background: T cells play an important role in bronchial asthma. Although airway CD4+
Tcells have been extensively studied previously, there are hardly any studies relating CD8+
T cell activation and disease symptoms.
Objectives: The aim of this study was to analyse the association between Tcell activation
in induced sputum T cells and asthma severity and control; and to evaluate T cell
subpopulations in the same subgroups.
Methods: Fifty allergic asthmatic patients were recruited and lung function testing was
performed. Airway cells were obtained by sputum induction via inhalation of hypertonic
saline solution. CD3, CD4, CD8, CD28, CD25 and CD69 were studied by flow cytometry in
whole induced sputum and peripheral blood cells.
Results: Total induced sputum Tcells and CD8+ Tcells had a higher relative percentage of
the activation markers CD25 and CD69 in comparison with peripheral blood. In sputum, the
relative percentage of CD25 was higher in CD4+ T cells when compared to CD8+ T cells and
the reverse was true regarding CD69. However, neither disease severity nor control were
associated with the relative percentage of CD25 or CD69 expression on T cells in sputum.
Conclusions: Both CD4+ and CD8+ Tcells are activated in the lungs and peripheral blood of
asthmatic patients. However, with the possible exception of CD69+ CD8+ T lymphocytes in
the sputum, there is no association between Tcell activation phenotype in the target organ
and disease severity or control.
& 2009 SEICAP. Published by Elsevier España, S.L. All rights reserved.SEICAP. Published by Elsevier Esp
ude.ubi.pt (L. Taborda-Barata).Introduction
Asthma is characterised by variable airflow obstruction,
airway hyperresponsiveness, and chronic airway inflamma-
tion, involving activated eosinophils, mast cells, and
T lymphocytes.1 It is known that airway inflammation is aaña, S.L. All rights reserved.
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assessed by bronchial biopsies or bronchoalveolar lavage
fluid (BAL). Examination of spontaneous or induced sputum
has advantages over these invasive methods, as it is
inexpensive, easy to perform, well-tolerated, non-invasive,
safe, and can be performed repetitively.2 The cellular
composition of sputum correlates well with that of BAL,
but to a lesser extent with that of bronchial biopsies.3,4 In
addition to cellular sputum composition, there is increasing
interest in the analysis of cellular subtypes and activation,
which can be performed using flow cytometry.5
Traditionally, type 2 CD4+ T cells (Th2), have been
regarded as the most important T cell subset in the
pathophysiology of asthma.6 CD8+ T cells are considered to
be of lesser importance in bronchial asthma. However,
increased numbers of activated CD8+ T cells in the airways
may cause acute tissue damage via the release of lytic
substances, such as perforin and granzymes. In this regard,
in chronic obstructive pulmonary disease (COPD), also an
inflammatory lung disease, CD8+ T cells contribute to the
abnormal inflammatory process, and play an important role
in the pathogenesis of disease. CD8+ T cells can be
subdivided into functional and phenotypically different
populations, on account of CD28 expression.7 CD28 is a co-
stimulatory receptor, constitutively expressed on approxi-
mately 95% of CD4+ T cells and 50% of CD8+ T cells in
humans, and is crucial for the activation and proliferation of
naive T cells.8 CD8+CD28+ T cells are predominant in young
healthy individuals and CD8+CD28 cells increase with
ageing and during inflammation and autoimmune disease.9
It was suggested that CD8+ T cells can contribute to the
pathology of asthma death due to an enhancement of pre-
existing airway inflammation in response to viral infec-
tion.10,11 Furthermore, human airway CD8+ T cells sponta-
neously produce increased type 1 and type 2 cytokines in
subjects with asthma, when compared to healthy controls.12
Both CD4 and CD8+T cells can express CD25, the
interleukin-2 receptor a-chain, which is a marker of both T
cell activation and Tcell proliferation. Both cell types, apart
from macrophages, eosinophils and neutrophils, may also
express the activation marker CD69.
Airway inflammation in asthma can have variable inten-
sity and biological features and, to a certain extent, may
have a relationship to disease severity.13 In fact, asthma
guidelines recommend stepwise increments in anti-inflam-
matory medication to control increased disease activity.14
However, few studies have analysed the relationship be-
tween disease severity and parameters of T cell activation.
The aims of this study were to compare T cell subpopula-
tions and activation status between peripheral blood and
induced sputum in asthma, and to correlate relative
percentages in induced sputum with severity and control
of the disease.Materials and methods
Volunteers
Fifty adult allergic asthmatics were recruited from the
Allergy Clinic of the Cova da Beira Hospital and lung function
testing was performed. Asthma was defined according to theAmerican Thoracic Society criteria.15 Allergy was confirmed
by clinical history, skin prick testing, and determination of
total and specific IgE. Asthma severity was assessed at the
first appointment, according to the Global Initiative for
Asthma (GINA) guidelines.16 According to the GINA guide-
lines asthma severity should be classified in the first
appointment according to: symptoms; amount of beta2-
agonists needed to treat symptoms; and lung function. Both
the level of airflow limitation and its variability enable
asthma to be subdivided by severity into four steps:
Intermittent, Mild Persistent, Moderate Persistent, and
Severe Persistent.
Asthma control was assessed by the Asthma Control Test
(ACT),17 just before the induction of sputum. Controlled
classes were merged, since the important comparison in the
study was between uncontrolled (score of less than 20 points
in ACT) and any kind of controlled patients (score equal to or
above 20).
None of the patients had changes in the medication or
respiratory infections in the month prior to the induction,
and none was on oral corticosteroids.
Twelve healthy volunteers were also recruited among the
personnel of the Cova da Beira Hospital.
The study was approved by the Hospital Ethics Committee
and all subjects gave written informed consent. The
procedures are in accordance with the World Health
Association and the Helsinki Declaration.Sputum induction
All patients were given detailed information and clear
instructions prior to the procedure. Before sputum induc-
tion, all patients inhaled 12 mg formoterol via a metered
dose inhaler.
Sputum was induced and processed according to
the method described by Pizzichini et al.,3 with minor
modifications.
Baseline peak expiratory flow (PEF) was measured prior to
induction, and the measurement was repeated following
formoterol, and after each 5 minute inhalation of nebulised
hypertonic saline (5%). The procedure was stopped if PEF
fell by 420% at any time, or if bothersome symptoms
occurred. After each period of inhalation, volunteers were
asked to rinse their mouth with water and blow their nose,
and attempt to cough sputum into a sterile container. The
cumulative duration of nebulisation was 15–20min.Sputum processing
Unselected sputum was weighed and 0.1% dithiothreitol
(DTT, Sigma-Aldrich, Saint Louis, MO, USA) in phosphate
buffered saline (PBS) was added at a ratio of 4ml to 1 g
sputum. The sputum was incubated with DTT at room
temperature for 15min on a rolling mixer. The same volume
of PBS (4ml to 1 g sputum) was added to the mixture and
incubated for another 10min. The suspension was then
filtered through a 40 mm cell strainer (Falcon). The filtrate
was centrifuged at 500 g for 10min at room temperature to
pellet cells. After two washing steps, cells were resuspen-
dend in PBS and viability was determined by tryptan blue
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ometer (Merck Eurolabs, Lutterworth, UK).PBMC preparation
Peripheral blood mononuclear cells (PBMC) were separated
from 20ml heparinised peripheral blood using Lymphoprep
(Nycomed, Oslo, Norway), washed twice in RPMI 1640 (Sigma
Aldrich) without additives, and counted.Flow cytometry
Sputum cells and PBMC were washed in PBS containing 0.1%
sodium azide (Sigma-Aldrich) and 0.4% bovine serum
albumin (Sigma-Aldrich) (staining medium) and centrifuged
at 300 g. For each test, approximately 500,000 lymphocytes
were incubated with fluorochrome stained antibodies for
30min at 4 1C in the dark. Cells were then washed,
resuspended in PBS and acquired using a FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA, USA). Up to
20,000 CD3 positive events were collected per sample. All
samples were stained with an APC-conjugated anti-human
CD3 monoclonal antibody (mAb), FITC conjugated anti-
human CD4 mAb, and PerCP conjugated anti-human CD8
mAb. To assess surface marker expression, samples were
incubated with anti-CD25, -CD69, or -CD28 PE-conjugated
mAbs (Becton Dickinson). Isotype-matched antibodies were
used as controls. The number of positive cells for each
surface marker was expressed as a percentage of CD4+ or
CD8+ cells. In the specific case of CD25, all events which
expressed a higher MFI for CD25 than the blank sample, (and
not only those with the highest intensity of expression) were







Age (years) 39715 49713DTT tests in peripheral blood
As sputum has to be homogenised before flow cytometry, a
possible effect of DTT treatment on surface markers has to
be considered. However, in contrast to peripheral blood
leukocytes, induced sputum leukocytes can only be obtained
with DTT treatment.
In order to evaluate the influence of DTT on surface for
the markers under study, we performed the same procedure
of sputum processing using peripheral blood. Half the
sample was treated with DTT and the other half with PBS
alone in the same proportion as that of sputum
(1 g peripheral blood: 4ml DTT or 4ml PBS). Afterwards
PBMC were isolated and stained as described.Sex (F/M) 14:5 11:9





Current smokers 3 4
Blood eosinophils (%) 2.4%72 3.8%73
Serum IgE (IU/ml) 1867152 5007612
Results are expressed as mean (7SE).
FEV1 ¼ forced expiratory volume in 1 second; FVC ¼ forced vital
capacity; FEF ¼ forced expiratory flow.Data analysis
Flow cytometry data were acquired and analysed using
CellQuest Software (Becton Dickinson). Data are expressed
as median and range. Wilcoxon signed rank test was used for
comparison within the same group, and Mann-Whitney U test
was used for comparison between two groups. A value of
po0.05 was considered significant.
Statistical analyses were performed using Minitab 14.Results
Characteristics of patients
Fifty allergic asthmatic patients were recruited for this
study.
Sputum was successfully induced in 45 patients; however,
flow cytometry could only be performed in 41 of the samples
due to insufficient number of T cells. Patients with different
asthma severities were paired regarding age and gender.
Twenty one patients (age 39715, 5 males) had intermittent
asthma and were not under inhaled corticosteroids. They
only resorted to rescue medication with short-acting b2-
agonists. Twenty patients had moderate persistent asthma
(age 49713, 9 males); all were receiving beclomethasone
dipropionate or equivalent (budesonide or fluticasone) daily
(median dose 500mg per day), 11 of them were also receiving
long-acting b2-agonists, and 6 were on anti-leukotrienes. In
the intermittent asthma group FEV1 was 106%712, FEV1/FVC
was 8277 and FEF 25-75 was 85%723. In the moderate
persistent asthma group FEV1 was 92%723, FEV1/FVC was
70710 and FEF 25–75 was 56%726. Patients were paired for
smoking (three in the intermittent group and four in the
moderate persistent group were smokers) (Table 1).
Regarding the healthy volunteers, no data are presented as
we were only able to collect enough Tcells on two occasions.
Sputum processing
Since DTT may affect results with sputum T cells, we also
performed DTT incubations with peripheral blood. No differ-
ences were seen in staining of any of the cell surface markers
(CD28, CD25 or CD69) on CD3+, CD4+ or CD8+ cells between
peripheral blood samples pre-treated with DTT plus buffer
(PBS), and those treated with buffer alone (Table 2).
Comparison between blood and sputum in all
asthmatic patients
There were significant differences in the CD4/CD8 ratio
between sputum and peripheral blood (3.6 vs. 2.0,
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Table 2 The effect of dithiothreitol (DTT) on the percentage of blood lymphocytes expressing CD28, CD25 and CD69 (n ¼ 6)
CD3+ CD4+ CD8+






















1.000 4.6 [1.5–9.0] 3.8 [2.3–9.4] 1.000
CD69 1.3 [0.7–5.5] 1.8 [0.7–5.7] 0.138 0.6 [0.1–5.4] 1.0 [0.2–5.5] 0.208 1.8 [1.6–5.1] 2.7 [1.4–4.8] 0.402
Figure 1 CD25 (panels A, D, and G, n ¼ 25), CD69 (panels B, E, and H, n ¼ 28), and CD28 (panels C, F and I, n ¼ 23) surface
expression in peripheral blood and induced sputum T cells from patients with intermittent and moderate persistent asthma.
The median value in each dataset is represented by a horizontal bar. Statistical analysis was performed with the Wilcoxon signed
rank test.
O. Lourenc-o et al288respectively, p=0.005). This difference was due to a
decrease in the levels of CD8+ T cells in induced sputum
(32.0% vs. 19.5%, p=0.001), with no difference in CD4+ Tcell
levels (63.0% vs. 73.5%, p=0.056).
In the present study, there were no significant differences
in relative percentages of CD8+CD28+ and CD8+CD28 Tcellsbetween peripheral blood and sputum (Figure 1I). Likewise,
there were no differences in the relative percentages of
CD4+CD28+ and CD4+CD28 T cells (Figure 1F).
The relative percentage of total T cells expressing CD25
and CD69 was significantly higher in sputum than in
peripheral blood (26.9% vs. 21.3%; p ¼ 0.027 and 57.7% vs.
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and B). Similar results were obtained for CD8+ T cells (11.5%
vs. 5.3%; p ¼ 0.001 and 74.4% vs. 4.8%; po0.001, for CD25
and CD69, respectively; Figures 1G and (H). In contrast, for
CD4+ T cells only CD69 expression was significantly higher in
sputum when compared to peripheral blood (49.0% vs. 2.2%;
po0.001; Figure 1E).
CD8+ Tcells had a significantly lower expression of CD25 and
CD28 than CD4+ T cells, both in induce ¼ d sputum (10.4% vs.
25.6%; p ¼ 0.001, and 55.6% vs. 94.6%; po0.001, for CD25 and
CD28 respectively) and in peripheral blood (5.1% vs. 30.0%;
po0.001, and 61.7% vs. 95.9%; p ¼ 0.001, for CD25 and CD28
respectively; Figures 2A and C). In contrast, CD8+ Tcells had a
significantly higher expression of CD69 than CD4+ T cells both
in sputum and peripheral blood (74.4% vs. 50.8%; p ¼ 0.001,
and 4.8% vs. 2.2%; p ¼ 0.007, respectively; Figure 2B).
Comparison between blood and sputum in patients
with intermittent asthma
To circumvent the possible inhibitory effect of inhaled
corticosteroids on lymphocyte surface markers, we analysed
the data referring only to intermittent asthmatics without
medication, both at the time of sputum induction, and in
the previous 2 weeks. We found results in these intermittent
patients to be similar to those reported in the whole study
population for the expression of activation markers in blood
and induced sputum (data not shown).Figure 2 Comparison of surface expression of CD25 (panel A, n=25), C
CD8+ Tcells from peripheral blood and induced sputum of patients with
each dataset is represented by a horizontal bar. Statistical analysis wa
Table 3 Expression of CD25, CD69 and CD28 in sputum tota






























Results are represented as median percentage and range, and comparisRelationship between severity and phenotype
in sputum
Asthma severity was classified according to GINA guidelines
and only intermittent or moderate persistent asthmatics
were recruited for this study. Since we were unable to pair
uncontrolled intermittent and moderate persistent asth-
matic patients for analysis, we show here results for
controlled intermittent and controlled moderate persistent
asthmatics alone.
There were no significant differences in the percentages
of any of the sputum Tcell subpopulations between patients
with controlled intermittent asthma and patients with
controlled moderate asthma. Likewise, no association was
found between relative expression in sputum lymphocytes of
CD25 or CD69 and the severity of asthma (Table 3).
Nevertheless, CD25 expression on CD8+ T cells from
peripheral blood was associated with disease severity, with
moderate persistent asthmatics having a higher percentage
of CD25 positive cells (8.7% vs. 2.1%, p=0.006; Figure 3) than
the intermittent asthmatics.Relationship between control and phenotype
in sputum
Asthma control was assessed prior to sputum induction by
the ACT test.D69 (panel B, n=28) and CD28 (panel C, n=23), between CD4+ and
intermittent and moderate persistent asthma. The median value in
s performed with the Wilcoxon signed rank test.





























ons were performed by Mann-Witney U test.
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into controlled (ACT above or equal to 20 points) or
uncontrolled (ACT below 20 points).
No association was found between relative expression in
sputum lymphocytes of CD28, CD25 or CD69, and the control
of asthma in moderate persistent asthmatics (Table 4).
Discussion
In the present study, we observed higher expression of
activation markers on sputum lymphocytes than on those in
peripheral blood, consistent with an inflammatory process
taking place in the lung. Interestingly enough, this heigh-
tened expression was predominantly significant in CD8+
T cells, which had higher expression of CD25 and CD69
activation markers. Only the percentage of CD69+ CD8+
T lymphocytes in the sputum showed a trend for association
with asthma severity or control.
We found a higher CD4/CD8 ratio in induced sputum when
compared to peripheral blood. Similar results have been
previously reported by other investigators in asthma,3 and
even in healthy volunteers.5 The CD4 : CD8 imbalanceFigure 3 Surface expression of CD25 in CD8+ T cells from
peripheral blood of patients with intermittent and moderate
persistent asthma. The median value in each dataset is
represented by a horizontal bar. Statistical analysis was
performed with the Mann-Whiney U test.
Table 4 Expression of CD25, CD69 and CD28 in sputum tota
controlled (n ¼ 6) and uncontrolled (n ¼ 6) moderate persistent
CD3+ CD4+

























Results are represented as median percentage and range, and comparisobserved in our study was due primarily to a reduced
percentage of CD8+ T cells. This may be due to the fact that
CD8+ T cells may compartmentalise more intensely than
CD4+ T cells within the submucosa rather than in the
mucosa. However, in contrast, other researchers have found
a tendency towards a high percentage of CD8+ T cells in the
BAL of asthmatic patients as compared with healthy
controls, resulting in a decreased CD4/CD8 ratio.18 In fact,
it has been shown that CD8+ T cells are more sequestered
than CD4+ T cells in the airway during an acute asthma
attack.18 Furthermore, the number of CD8+ cells in
bronchial biopsies in patients with asthma has been
associated with disease outcomes, as determined by loss
of lung function.19 Indeed, activated CD8+ T cell infiltration
in peribronchial tissue has been associated with asthma
death.10 Discrepancies between these results and ours may
be due to the fact that different populations of asthmatic
patients were studied, namely in terms of disease severity.
In the present study we did not find any significant
differences between the percentages of either CD28-
expressing CD4+ or CD8+ lymphocytes in sputum and
peripheral blood. Although the low numbers of volunteers
may account for the observed lack of differences, it should
be borne in mind that effector T cells are less dependent on
CD28 and their survival relies on extrinsic factors, such as
IL-2, which are produced during activation.20 This may
suggest that T cells found in the lung in the context of
asthma are not different from those in peripheral blood, in
terms of co-stimulatory requirements.
We also show here that in both total CD3+ cells and CD8+
T cells, the activation markers CD25 and CD69 were
expressed in a higher relative percentage in sputum than
in peripheral blood. Leckie et al. reported similar results to
ours: both in asthmatics and healthy controls, CD8+ T cells
from sputum had higher percentage of CD69 expression than
CD4+ cells. There were also higher percentages of both CD4+
and CD8+ cells expressing CD69 in sputum than in peripheral
blood.5 However, these authors failed to stain T cells with
anti-CD3 mAb. Instead, they used anti-human CD45 mAb to
exclude other non-leukocyte events. This might lead to the
inclusion of CD8+ NK cells in the analysis. Moreover, the
Leckie study only included eight ‘‘very mild’’ asthmatics,
while in the present study, we performed comparisons based
on severity between 11 subjects with intermittent asthma
and 6 subjects with moderate persistent asthma, as well asl lymphocytes, CD4+ and CD8+ T cells from patients with
asthma.
CD8+






















ons were performed by Mann-Witney U test.
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and 6 subjects with uncontrolled asthma. In another report,
Ortega et al. assessed the presence of activated bronchial
lymphocytes in induced sputum of asthmatic patients and
healthy controls. Lymphocytes from asthmatics showed an
increased surface expression of activation markers (CD25 in
T cells, and CD23 in B cells) when compared to lymphocytes
of healthy non-atopic subjects.21 However, this study only
evaluated total T cells, while in our study we analysed both
CD4+ and CD8+ subpopulations. Therefore, using a more
detailed methodological approach, our study confirms and
expands previous results observed by others. In our case, we
could not compare our results with those obtained from
healthy controls since only in two cases out of twelve were
we able to analyse T lymphocytes. This suggests that only a
minor fraction of healthy volunteers from our population, in
the absence of any pro-inflammatory stimulus, may have
significant numbers of lymphocytes in the airways.
Our previous results with phenotypic markers could have
been influenced by sputum processing using DTT. However,
we believe that this is not the case because adding the same
concentration of DTT, as used in sputum processing protocol,
to whole blood from six allergic asthmatic patients did not
influence the expression of the markers under study.
Furthermore, other studies have also shown that DTT has
no effect on the expression of CD69 and other surface
markers.5,22
We could not observe any relationship between asthma
severity and the percentage of total CD4+ or CD8+ T cells
expressing the activation markers CD25 or CD69 in induced
sputum. A highly plausible explanation for not finding any
difference in surface marker expression is the small number
of participants in this study. In contrast, in peripheral blood,
CD25 expression was increased on CD8+ Tcells from patients
with moderate persistent asthma as compared with patients
with intermittent asthma.
We did not observe any association between of CD28 on
sputum T lymphocytes and asthma severity, In this regard,
our results are not in agreement with those from a previous
report. Hamzaoui et al. studied, for the first time, the
expression of CD28 on CD8+ cells in induced sputum.
CD8+CD28 cells were found to be more expanded and
expressed lower levels of IFN-g in severe asthmatics than in
mild asthmatics and age-matched healthy controls.23 How-
ever, the authors did not include CD3 in the flow cytometric
evaluation, including as CD8+ T cells probably other non-
T cells (namely NK cells) which may also express CD8.
Reasons that may account for our failure to observe a
relationship between asthma severity and the biological
parameters analysed in the sputum in our study may include
the fact that we studied low numbers of patients. Another
reason may be our patients with moderate asthma were on
inhaled corticosteroids. In fact, treatment with inhaled
corticosteroids could have had a confounding effect on
analysis of airway inflammation, as it has been demon-
strated to reduce expression of some activation markers.24
Alternatively, disease severity may rather be related to
changes in function than the percentage or phenotype of
CD8+ T cells in the bronchi of patients with asthma.
Independently of disease severity, it is important to
monitor control of disease. In our study, no significant
association was found between relative expression of CD28,CD25 or CD69 on sputum lymphocytes and the control of
asthma. However, it should be stressed that expression of
CD69 on sputum CD8+ T lymphocytes showed a trend
towards being significantly increased in moderately severe
asthma, when controlled patients were compared with
uncontrolled patients (82.4 (71.3–89.4) vs 62.5
(50.0–80.2); p ¼ 0.055). This may suggest that activated
CD8+ T lymphocytes with a regulatory role (but not of the
CD28- subtype) or with a Tc1 type of cytokine pattern may
be associated with better asthma control. In this sense, it
has been shown that CD8+ T cells are important immunor-
egulatory cells in some animal models of respiratory allergic
disease.25 This possibility should be addressed in a sub-
sequent study involving a larger number of patients. In fact,
it is possible that the lack of significant association between
asthma control and phenotypic activation markers or CD28
may be due to the fact that we included few patients or that
all moderate persistent asthmatics were taking inhaled
corticosteroids. Studies with a different design, allowing
suspension of medication may also help to clarify this issue.
In summary, in this study we show that CD4+ and CD8+
T cells are activated in the lung, which may suggest that
both subpopulations are participants in the inflammation
process at the target organ. However, we have not been able
to demonstrate a relationship between activation of T cell
subsets and severity of asthma or asthma control, except for
a trend for a higher percentage of CD69+ CD8+
T lymphocytes in the sputum to be associated with control.
Further studies are needed in order to characterise the
inflammatory and regulatory function of T cells in the lung,
mainly the CD8+ subpopulation.Conflict of interest statement
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